In this review, we detail the changes and the relevant features that are applied to
neuroendocrine neoplasms (NENs) in the 2022 WHO Classification of Endocrine and …

Abstract The American Joint Committee on Cancer (AJCC) staging system for all cancer
sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be …

Background & Aims Next-generation sequencing (NGS) of pancreatic cyst fluid is a useful
adjunct in the assessment of patients with pancreatic cyst. However, previous studies have …

Cancer risk is modulated by hereditary and somatic mutations, exposures, age, sex, and
gender. The mechanisms by which sex and gender work alone and in combination with …

This review provides an overview of novel insights in the clinical management of patients
with Multiple Endocrine Neoplasia Type 1, focusing on the last decade since the last update …

Histopathological classifications of neuroendocrine neoplasms (NEN) change regularly and
the latest WHO classification published in 2022, which concerns all NEN in the body …

Purpose Neuroendocrine neoplasms can occur as part of inherited disorders, usually in the
form of well-differentiated, slow-growing tumors (NET). The main predisposing syndromes …

Background/objectives Death domain-associated protein (DAXX) and/or α-
thalassemia/mental retardation X-linked (ATRX) chromatin remodeling genes mutations and …

Simple Summary ATRX is one of the most frequently mutated tumor suppressor genes in
human cancers. ATRX protein is a chromatin remodeler and transcriptional regulator that is …

Little is known about the morphomolecular features of G3 neuroendocrine tumors (G3NETs)
under prolonged systemic treatments, although rapid progression is increasingly observed …